Abstract
Objective: To review COVID-19 and possible treatment with Angiotensin II receptor blockers (ARB’s) in patients who developed severe acute respiratory syndrome. Methods: Review study of the literature in the databases PubMed, Medline, Scielo, Elsevier and Google academic, from 2000 to 2020 based on the descriptors: "coronavirus", "treatment", "antihypertensive" and "severe acute respiratory syndrome". Results: From the literary search of the pathology, epidemiology and molecular biology of COVID-19 and pharmacology of the ARBs, 49 works were read completely and, at the end, a total of 31 articles were selected to contemplate the study, being these classified according to the theme, author/year and type of study, being 71% (22) published in 2020 and 3.2% (1) to other years. Among the topics covered, 25.8% (8) approach "COVID-19/Sars-Cov-2 and the clinical and molecular aspects", followed by "Cytokine Storm and the immune response" (16.1%). Final considerations: This bibliographic review aggregates information that indicates the benefits of using Bras in the treatment of severe acute respiratory syndrome caused by COVID-19, therefore, there is consensus on the guidelines for not suspending Bras in the course of COVID-19 infection. However, proving the efficacy of the drug requires more specific laboratory experiments.